To view this email as a web page, click here.
 
Generic naloxone nasal spray gets green light from FDA
Providing another tool to fight the opioid epidemic, FDA cleared the first generic naloxone hydrochloride nasal spray (Narcan) for use in a community setting.
Read more
 
FDA clears first non-drug option to treat ADHD in children
FDA cleared the first medical device to treat attention deficit hyperactivity disorder (ADHD) in children.
Read more
 
The biggest obstacle to cancer biosimilar development
From our sister brand, Managed Healthcare Executive: Biosimilars could help alleviate high oncology drug costs, but many challenges remain for development and adoption of biosimilars in the US.
Read more
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.